For multiple myeloma patients, B-cell maturation antigen (BCMA) is an ideal target of CAR-T therapy, except for the on-target/off-tumor toxicity against normal circulating plasma cells [5]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.